The impact of prior therapies on overall survival in mCRPC patients receiving Lu-PSMA-617 therapy. A WARMTH retrospective multicenter trial

Nuklearmedizin 2020; 59(02): 93-94
DOI: 10.1055/s-0040-1708133

Leuchttürme

Leuchtturm-Sitzung 3: Theranostics

H Ahmadzadehfar

¹University Hospital Bonn, Nuklearmedizin, Bonn

,

K Rahbar

²University Hospital Muenster, Nuklearmedizin, Münster

,

RP Baum

³Center for Precision Radiomolecular Oncology, Bad Berka

,

C Gerke

¹University Hospital Bonn, Nuklearmedizin, Bonn

,

C Kratochwil

⁴University Hospital Heidelberg, Nuklearmedizin, Heidelberg

,

H Ilhan

⁵University Hospital Munich, Nuklearmedizin, Munich

,

M Sathekge

⁶University of Pretoria & Steve Biko Academic Hospital, Nuklearmedizin, Pretoria

,

L Kabasakal

⁷Istanbul University, Nuklearmedizin, Istanbul

,

F. O Garcia-Perez

⁸Instituto Nacional de Cancerología Mexico, Nuklearmedizin,, Mexico

,

K Kairemo

⁹Docrates Cancer Center, Nuklearmedizin, Helsinki

,

M Maharaj

¹⁰Nuklearmedizin, Durban

,

D Paez

¹¹International Atomic Energy Agency, Nuclear Medicine and Diagnostic Imaging Section, Vienna

,

I Virgolini

¹²Medical University Innsbruck, Nuklearmedizin, Innsbruck